August 2025 update of the reimbursable companion diagnostics list in Belgium

In Belgium, there is a “coupled reimbursement” framework for companion diagnostic tests, maintained and updated by the Belgian National Institute for Health and Disability Insurance (INAMI/RIZIV), which includes:

• Generic codes in Article 33ter of the INAMI/RIZIV Nomenclature, with fees based on the level of test complexity (1 for the lowest, 3 for the highest);
• A list of reimbursable predictive biomarkers (Chapter VIII-c of the reimbursable pharmaceuticals list), each linked to a specific pseudocode and corresponding Article 33ter code. This list is updated monthly;
• A list of “personalized” medicines (Chapter VIII-b of the reimbursable pharmaceuticals list) for which the use of a CDx test is required. The associated tests are specified in the reimbursement conditions, and the list is updated monthly.

August 2025 update of the list of reimbursable predictive biomarkers (Chapter VIII-c) includes the addition of one new biomarker: “Analysis of BRAF V600 mutation status in glioma” (level 1, diagnostic investigation).

See full details in French here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.